MRK

Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.

MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.

NEW YORK--(BUSINESS WIRE)--Merck, through the company's Merck for Mothers initiative, and Mae are collaborating on a multi-state effort to expand and sustain the community-based doula workforce, with a goal of advancing maternal health equity and access for those experiencing the most disparate outcomes. The collaboration will advance doula training, professional development, and ongoing administrative support towards Medicaid participation for community doulas. It will also allow Mae to extend.

Bank of America has predicted that the Federal Reserve will be forced to raise interest rates by 75 basis points this year, with the first 25-basis-point hike in September.

ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.

I continue to believe that Merck & Co., Inc. has an attractive risk/reward profile. Ten days ago, on June 12, the FDA approved both Keytruda and Keytruda Qlex in combination with Welireg for the treatment of a type of kidney cancer called earlier-stage ccRCC. Overall, this "trio" generated $8.23 billion in sales for Merck in Q1, up 12.1% year-over-year.

Merck ​said on ‌Monday its ​drug ​met the ⁠main ​goal in ​a late-stage trial ​testing ​it in ‌patients ⁠with a type ​of ​inflammatory ⁠bowel disease.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderately to severely active UC. The study successfully met its primary endpoint of clinical remission according to the Modified Mayo Scor.

In the closing of the recent trading day, Merck (MRK) stood at $113.87, denoting a -1.36% move from the preceding trading day.

The U.S. FDA on Thursday approved an expanded indication for Merck & Co Inc.'s (NYSE:MRK) Capvaxive, extending its use to children and adolescents ages 2–17 with chronic conditions who have completed a primary pneumococcal vaccine series.